View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
January 5, 2022updated 07 Jan 2022 5:36pm

Coronavirus company news summary – Pfizer to supply oral therapy courses to US – Dr Reddy’s to offer generic version of Merck pill

The US Government has agreed to procure additional ten million courses of Pfizer’s Covid-19 oral therapy, Paxlovid (nirmatrelvir and ritonavir). This is apart from the commitment to purchase ten million courses of Paxlovid under a previous contract by the government. The latest deal takes the number of courses to be supplied to the US to a total of 20 million. The initial courses will be delivered by June end while the remaining pills will be supplied by September this year.

Indian company Dr Reddy’s Laboratories is set to introduce the generic version of Merck’s (MSD) antiviral pill for Covid-19, molnupiravir, at a cost of nearly $0.5 (Rs35) per capsule. To be administered as a five-day course treatment of 40 capsules, molnupiravir will be marketed under the brand name Molflu in the country. According to the company, the complete course will be priced at $18.77 (Rs1,400).

Israeli Prime Minister Naftali Bennett said that a fourth dose of vaccine for Covid-19 demonstrated a five-fold rise in antibodies a week after vaccination, in a study. The trial inoculated medical personnel with the fourth dose of Pfizer and BioNTech’s vaccine. The country is currently offering fourth booster shots to individuals aged over 60 years, healthcare workers and immunocompromised people.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology